Annual Meeting of the Japanese Society of Toxicology
The 46th Annual Meeting of the Japanese Society of Toxicology
Session ID : S8-1
Conference information

Symposium 8
Case study: Non clinical study outcomes of Fasiglifam discontinued prior to approval-Consideration from non-clinical toxicity study results
*Hideo FUKUI
Author information
CONFERENCE PROCEEDINGS FREE ACCESS

Details
Abstract

GPR40 is highly and dominantly expressed in pancreatic beta cells and is activated by medium- to long-chain free fatty acids (FFAs) to potentiate glucose stimulated insulin secretion. Fasiglifam was a novel, oral, and selective small molecule agonist of GPR40 under development as a once-daily treatment for type 2 diabetes. Unfortunately, a development program was terminated late in phase III clinical trials due to liver safety concerns. Three important serious liver injury cases were identified among around 9100 patients treated with Fasiglifam; one case was adjudicated to be a clear Hy’s Law case [ALT or AST > 3 x ULN (upper limit of normal) and total bilirubin > 2 x ULN] and the two remaining cases were considered to closely approximate Hy’s Law cases. Fasiglifam-related liver toxicity was also observed in repeat-dose dog toxicity studies. It was characterized by elevation of plasma AST, ALT, ALP, and /or bilirubin and portal/periportal granulomatous inflammation with crystal formation in histopathology. This toxicity was observed in a 4-week study at 1000 mg/kg/day. The toxicity measures were greater than those observed at 150 and 80 mg/kg/day in 13- and 39-week studies, respectively, indicating that the toxicity was both dose- and duration-dependent. We analyzed the composition of foreign body materials observed in dog liver and identified Fasiglifam and Fasiglifam glucuronide. Although elevations of serum bilirubin and ALT were observed in repeat-dose rat studies, no histopathological changes indicative of liver injury were observed in any rat studies even at the lethal dose of 2000 mg/kg/day. In this symposium, the mechanisms for liver toxicity of Fasiglifam in dogs, safety margins in plasma and bile, human relevancy and discussion with FDA and PMDA would be introduced.

Information related to the author
© 2019 The Japanese Society of Toxicology
Previous article Next article
feedback
Top